Background: Human herpesvirus 6 (HHV6) is a cause of post-transplant acute limbic
| INTRODUC TI ON
In immunocompetent persons, human herpesvirus 6B (HHV-6B) is encountered in early childhood and often manifests as a febrile illness, rash, and febrile seizure with an estimated seroprevelence of greater than 95% after 2-3 years of age. [1] [2] [3] Reactivation of this virus is most commonly encountered in individuals with induced immunocompromised states such as patients with hematologic or solid organ malignancy, HIV/AIDS, or hematopoetic stem cell transplantation.
Reactivation has a very heterogenous clinical presentation and can include fever, pneumonititis, hepatitis, thrombytopenia, seizures, and profound encephalitis with marked amnesia. 1, [3] [4] [5] In the setting of increased utilization of hematopoetic stem cell transplantation, HHV-6B has been identified as a major cause of post-transplant acute limbic encephalitis (PALE) in both children and adults. 6, 7 Seizures and epilepsy are both acute, and long term, issues associated with this disorder yet interestingly no biomarkers or association with viral load have been identified as predictors of disease. 1, [6] [7] [8] The goal of this study was to retrospectively evaluate lab and neurodiagnostic biomarkers in pediatric patients with HHV-6B associated PALE as potential predictors of seizure during their acute clinical course.
| PATIENTS AND ME THODS

| Cohort identification
A retrospective chart based review was conducted after obtaining institutional IRB approval for patients evaluated at our institutions between 2000 and 2017. Patients were identified through STRIDE clinical database by searching for all patients who were less than 18 years of age, had a lumbar puncture performed, and had HHV6
(quantitative real-time PCR) independently or batch (as part of meningoencephalitis panel) tested. Patients' clinical data were further reviewed if they (a) had a lumbar puncture, and (b) tested positive for HHV-6.
| Inclusion criteria and definitions
Patients were included in this study if they met clinical criteria for HHV-6 associated PALE. Clinical criteria for PALE were based off prior studies and defined as presence of clinical symptoms of encephalitis (altered mental status, amnesia, seizure, confusion, disorientation, etc.) with acute/subacute onset in a patient who was previously neurocognitively normal. 1 All patients had to have tested positive for HHV-6 by PCR and also have exclusion of other primary neurology etiologies that could explain symptoms. 5 
| Analysis
Continuous variables (age, time to infection, serum HHV6 viral load, CSF studies including HHV-6 viral load, cellularity, protein, and glucose) were examined for normality using a combination of histograms, Shapiro-Wilks test and skew/kurtosis; non-normal data were summarized using the median and interquartile range, whereas normally distributed data were summarized with means and standard deviation.
Categorical data (gender, abnormal MRI, hyponatremia, presence of sepsis, seizure) were summarized using frequency and percentages. Group means were compared using two-tailed t tests; medians were compared with the non-parametric Mann-Whitney U test. Dichotomous variables were compared using the Fisher exact test. A linear regression analysis was used to control for potentially confounding covariates. An alpha of P < 0.05 was predetermined as a threshold for statistical significance.
| RE SULTS
A flowchart of inclusion and exclusion of patients in this study is presented in Figure 1 ; clinical and demographic data are shown in Table 1 . In total, 11 patients were identified, all of whom had undergone hematopoietic stem cell transplantation. Of this group, eight had allogenic transplants and three had autologous transplants with the most frequent indication being hematologic malignancy. The mean age of all patients in this study was 8.3 years. Mean age of those who had seizures (6.0 years) was lower than those who did not, although this did not reach statistical significance (P = 0.27).
There were nine males total (81%) in the cohort with no difference in gender between those who had seizures.
Infection, clinical course, and neurodiagnostic data are presented in Table 2 . All patients were diagnosed as HHV-6B positive. The
TA B L E 1 Baseline demographic and clinical variables N 11
Age at onset (y) Natural log CSF HHV6 viral load 10.7 ± 0.8
Natural log serum HHV6 viral load 11 ± 0.9
Values are mean ± SE for normally distributed variables, median (interquartile range) for skewed variables, and frequency (%) for dichotomous variables.
HSCT, hematopoietic stem cell transplant. Concurrent hyponatremia and sepsis were identified in three patients each with two having both present at the time of first seizure.
No seizures
Routine (spot) EEG was performed in five patients with abnormalities noted in 80% of patients. Only one patient without seizure had an EEG and this study was normal. Neuroimaging with MRI was performed in seven patients and was abnormal in three, most commonly noting T2 hyperintensities in the temporal lobes. Negative studies were performed an average of 5 days after diagnosis, whereas positive studies were performed an average of 10 days after diagnosis.
Serum and CSF viral load data are presented in Tables 1 and 2 . Median serum viral load in patients with seizure was elevated at 566 000 copies/ mL compared to 36 340 (P = 0.10). CSF viral load was lower in patients with seizure at 2586 copies/mL compared to 473 979 copies/mL in patients without seizure as part of their clinical presentation (P = 0.02).
There were no statistically significant differences in other components 
| D ISCUSS I ON
This study identified that in a small cohort of pediatric patients with PALE, lower CSF HHV-6B viral load was significantly associated with subsequent development of seizures. Patients were also noted to be younger and have EEG abnormalities although neuroimaging abnormalities were not acutely detected. These findings are of utility in that they provide potential risk stratification biomarkers for pediatric patients with PALE with regards to development of seizures and epilepsy.
The mechanism underlying this observation remains speculative.
Patients who seized were younger on average compared to those who did not. Although this study utilized a lab method that could not assess primary infection vs reactivation of HHV-6B directly, lower viral loads have previously been observed in patients with primary infection, which is also more commonly seen in younger individuals. [10] [11] [12] [13] [14] The high seroprevalence of the virus earlier in life serves as additional support for this hypothesis. 1, 2 We thus speculate that primary infection, rather than reactivation, may increase the risk of seizure. Moreover, the converse of this (elevated CSF viral loads) have been observed in both latent and chromosomally integrated reactivation of HHV-6 in immunocompromised patients. 12, 13 Chromosomal integration of HHV-6 is rare, occurring in a small minority of patients (1%-2%). 15 As these patients have high levels of HHV-6 DNA integrated into the cells, they often test positive for the virus as a result of normal cell turnover although they remain asymptomatic. 16 This phenomenon is not likely to have not impacted the findings presented in this report given the rarity. Overall, our findings raise the possibility that the pathogenesis of PALE in patients with primary infection may differ from those with reactivation, especially in the context of seizure and epilepsy.
11-17
CSF cell counts were uniformly insignificant in this study and may represent the sequelae of immunosuppression and the patients' inability to mount an immune response against viral infection, although this was not assessed directly.
5,12
Nearly, every patient with seizures had an abnormal EEG in this study. Although previously identified as abnormal in HHV6-associated PALE, EEG is unstudied as a screening tool in this population. 17 The high rate of EEG abnormalities in our cohort underscores the utility of this neurodiagnostic study in risk stratification although an adequate control population was not established. Neuroimaging was less consistent with regards to identification of abnormal findings although this may be a time-dependent effect, as studies performed later appeared to
be more likely to demonstrate the classic findings of HHV-6 associated PALE. [5] [6] [7] In evaluating the utility of neuroimaging, prior studies have not demonstrated utility for this biomarker and prediction of acute epilepsy although long-term epilepsy may be associated with abnormalities. 8, 18, 19 This study has several limitations worth noting. First, our retrospective search criteria may have missed cases made by clinical present. This finding has been reported in adult cases although the degree of encephalopathy in all patients was mild to moderate with neurologic examination present, making it less likely that subclinical seizure activity was co-occuring. 6 The most relevant limitation to this study was the inability to accurately assess if patients had primary or secondary infection based on the assay utilized in all cases. In addition, it was not possible to directly assess if patients had chromosomal integration of the HHV-6B virus with subsequent reactivation, as the appropriate assay for testing this was not performed.
In summary, this study identifies that lower CSF HHV-6B viral load may convey a higher likelihood of seizure in pediatric patients who are post stem cell transplant. Whether this finding is indicates primary infection versus reactivation will need to be studied further.
Given the potential increased risk of seizure/epilepsy in this fragile population, additional work up with EEG, neuroimaging, and prophylactic anticonvulsants may be warranted.
